AstraZeneca shares slump on merger report

AstraZeneca’s shares fell roughly 7% on Monday after the Financial Times reported that the British drugmaker had discussed a possible merger with US-based Bristol Myers Squibb.

Although neither company confirmed the discussions, the report sparked uncertainty among investors and erased billions from AstraZeneca’s market value. The sharp fall marked AZ’s biggest one-day decline since 2020 as investors questioned the need for such a massive deal.

If completed, the deal could create a pharmaceutical giant worth about $400 billion, making it one of the biggest healthcare mergers in history.

The report caught many industry experts off guard because AstraZeneca has been one of the fastest-growing drugmakers in recent years. Led by CEO Pascal Soriot, the company has expanded its portfolio of medicines and is aiming to generate $80 billion in annual revenue by 2030.

Some analysts believe a merger could help AstraZeneca strengthen its position in the US, the world’s largest pharmaceutical market, and build an even larger cancer-treatment business by combining the two companies’ drug portfolios.

However, others questioned whether such a deal is necessary, given AstraZeneca’s strong financial performance and promising pipeline. 

Bristol Myers Squibb, on the other hand, is preparing for slower growth as several of its top-selling drugs lose patent protection and face cheaper generic competition.

For now, the merger remains only a reported possibility, and there is no indication that the talks will result in a final agreement.